REGULATION OF MONOCYTE RECRUITMENT INTO THE ISCHEMIC MYOCARDIUM BY THE ACE2 AXIS
ACE2 轴对单核细胞募集至缺血心肌的调节
基本信息
- 批准号:8646994
- 负责人:
- 金额:$ 11.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-04-01 至 2014-12-31
- 项目状态:已结题
- 来源:
- 关键词:Adoptive TransferAngiotensin IIAnimalsAreaAwardBasic ScienceBindingBiologyBone MarrowCardiacCardiologyCardiovascular DiseasesCardiovascular systemCellsChemotaxisChimera organismClinicalClinical TrialsCoronary ArteriosclerosisDataDevelopmentDevelopment PlansDoctor of PhilosophyExposure toFibrosisFigs - dietaryFlow CytometryFunctional disorderGoalsHealedHeart failureHematopoieticImmuneImmunologyIn VitroIndividualInfarctionInfiltrationInflammationInflammatoryInflammatory ResponseInfusion proceduresInjuryInstitutionInternal MedicineIschemiaKnowledgeLeadLeft Ventricular DysfunctionLeft Ventricular FunctionMediatingMediator of activation proteinMedicalMentorsMentorshipMorbidity - disease rateMusMyocardialMyocardial InfarctionMyocardial IschemiaMyocardiumNaturePathway interactionsPatientsPeptidesPeptidyl-Dipeptidase APeripheralPhysiciansPlayPopulationPrincipal InvestigatorProcessPublic HealthReceptor ActivationRegulationRegulatory PathwayRenin-Angiotensin SystemReperfusion InjuryReperfusion TherapyResearchResearch PersonnelResourcesRoleScientistSignal TransductionSupplementationSurfaceTestingTherapeuticTimeTissuesTrainingTransgenic AnimalsTranslatingUnited StatesUniversitiesWashingtonWound Healingangiogenesisautocrinebasecareer developmentcell typeclinically relevantcytokineexperiencehealingimprovedin vivoinhibitor/antagonistknockout animalmacrophagemembermonocytemortalitynovel therapeutic interventionnovel therapeuticspreventreceptorreceptor expressionresearch studysuccesstrafficking
项目摘要
DESCRIPTION (provided by applicant): The goal of this proposal is to develop the principal investigator (PI) into an independent physician- scientist in the field of cardiovascular research.
The PI has already undergone both intensive PhD training in the basic science field of immunology and significant additional training in cardiovascular research, both basic science and translational in nature. The PI has completed clinical training in internal medicine and is currently completing the final year of cardiology subspecialty training. The following 5-year career development plan will provide further refinement and training for the PI in order to gain research independence at the conclusion of the award. Dr. Douglas Mann, Chief of Cardiology at Washington University, will mentor the PI. Dr. Mann is a recognized leader in myocardial inflammation and has a tremendous breadth of experience, from defining the role of pro-inflammatory cytokines in heart failure to taking that knowledge and spearheading a clinical trial based on his results. As such, he serves as a perfect example of a successful physician-scientist that is able to translate basic science research into the clinical arena. The PI will tak advantage of this mentorship and the enormous basic science and clinical resources available at Washington University, one of the nation's premier academic institutions, in order to define a new area of clinically relevant basic science research. Myocardial infarction (MI) is a leading cause of morbidity and mortality in the United States and our understanding of the underlying mechanisms remains incomplete. Monocytes are the dominant cell type infiltrating the myocardium in the first week following MI. Unfortunately, little is known about the regulatory factors governing monocyte recruitment despite the fact that excessive recruitment leads to impaired infarct healing. Recent evidence suggests that pathological activation of angiotensin II (AngII) is directly involved in monocyte recruitment following ischemic injury. Angiotensin converting enzyme 2 (ACE2) is a critical endogenous AngII counter-regulator and acts not only to degrade AngII, but produces Ang1-7, a biologically active peptide that binds the Mas receptor (MasR). Enhancing the activity of any component of the ACE2 / Ang1-7 / MasR axis limits myocardial ischemic injury, however the interplay between the ACE2 axis and monocyte recruitment has not been assessed. We hypothesize that a monocyte-localized ACE2 / Ang1-7 / MasR axis exists, and is required to prevent both excessive monocyte recruitment and subsequent monocyte-mediated cardiac dysfunction following myocardial ischemia. By utilizing knockout and transgenic animals that target each member of the ACE2 / Ang1-7 / MasR axis, we will answer important mechanistic questions that define how the ACE2 axis governs monocyte recruitment and how altered recruitment impacts infarct healing. The answers to these questions may have broad clinical implications to the treatment of ischemic heart disease.
描述(由申请人提供):本提案的目标是将主要研究者(PI)培养为心血管研究领域的独立医生-科学家。
PI已经接受了免疫学基础科学领域的密集博士培训和心血管研究方面的重要额外培训,包括基础科学和转化性质。PI已完成内科临床培训,目前正在完成心脏病学专科培训的最后一年。以下5年职业发展计划将为PI提供进一步的完善和培训,以便在获奖结束时获得研究独立性。华盛顿大学心脏病学主任道格拉斯曼博士将指导PI。Mann博士是心肌炎症领域公认的领导者,拥有丰富的经验,从定义促炎细胞因子在心力衰竭中的作用,到利用这些知识并根据他的结果带头进行临床试验。因此,他是一个成功的医生,科学家,能够将基础科学研究转化为临床竞技场的完美例子。PI将利用这种指导以及华盛顿大学(美国首屈一指的学术机构之一)提供的大量基础科学和临床资源,以确定临床相关基础科学研究的新领域。 心肌梗死(MI)是美国发病率和死亡率的主要原因,我们对潜在机制的理解仍然不完整。单核细胞是MI后第一周浸润心肌的主要细胞类型。不幸的是,尽管事实上,过度募集导致受损的梗死愈合,但对单核细胞募集的调控因素知之甚少。最近的证据表明,血管紧张素II(AngII)的病理激活直接参与缺血性损伤后单核细胞的募集。血管紧张素转化酶2(ACE 2)是一种重要的内源性AngII反调节因子,不仅降解AngII,而且产生Ang 1 -7,一种结合Mas受体(MasR)的生物活性肽。增强ACE 2/Ang 1 -7 / MasR轴的任何组分的活性限制心肌缺血性损伤,然而ACE 2轴和单核细胞募集之间的相互作用尚未评估。我们假设单核细胞定位ACE 2/Ang 1 -7 / MasR轴存在,并且需要防止过度单核细胞募集和随后的心肌缺血后单核细胞介导的心功能障碍。通过利用基因敲除和转基因动物靶向ACE 2/Ang 1 -7 / MasR轴的每一个成员,我们将回答重要的机制问题,定义ACE 2轴如何管理单核细胞的招聘和如何改变招聘影响梗死愈合。这些问题的答案可能对缺血性心脏病的治疗具有广泛的临床意义。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Communication in the heart: the role of the innate immune system in coordinating cellular responses to ischemic injury.
- DOI:10.1007/s12265-012-9410-7
- 发表时间:2012-12
- 期刊:
- 影响因子:3.4
- 作者:Epelman, Slava;Mann, Douglas L.
- 通讯作者:Mann, Douglas L.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Slava Epelman其他文献
Slava Epelman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Slava Epelman', 18)}}的其他基金
REGULATION OF MONOCYTE RECRUITMENT INTO THE ISCHEMIC MYOCARDIUM BY THE ACE2 AXIS
ACE2 轴对单核细胞募集至缺血心肌的调节
- 批准号:
8450766 - 财政年份:2012
- 资助金额:
$ 11.32万 - 项目类别:
REGULATION OF MONOCYTE RECRUITMENT INTO THE ISCHEMIC MYOCARDIUM BY THE ACE2 AXIS
ACE2 轴对单核细胞募集至缺血心肌的调节
- 批准号:
8274020 - 财政年份:2012
- 资助金额:
$ 11.32万 - 项目类别:
相似海外基金
Early endothelial function activation by angiotensin II receptor blockers prevents vascular damage in a model of diabetes
血管紧张素 II 受体阻滞剂早期激活内皮功能可预防糖尿病模型中的血管损伤
- 批准号:
493141 - 财政年份:2023
- 资助金额:
$ 11.32万 - 项目类别:
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
- 批准号:
10734120 - 财政年份:2023
- 资助金额:
$ 11.32万 - 项目类别:
Role of Angiotensin II in Bladder Dysfunction
血管紧张素 II 在膀胱功能障碍中的作用
- 批准号:
10707997 - 财政年份:2022
- 资助金额:
$ 11.32万 - 项目类别:
Regulation of nuclear calcium and ROS by Angiotensin II in heart cells. Régulation du calcium et ROS nucléaires par l'angiotensine II dans les cellules cardiaques.
血管紧张素 II 对心脏细胞中核钙和 ROS 的调节。
- 批准号:
RGPIN-2016-04414 - 财政年份:2022
- 资助金额:
$ 11.32万 - 项目类别:
Discovery Grants Program - Individual
Role of Angiotensin II in Bladder Dysfunction
血管紧张素 II 在膀胱功能障碍中的作用
- 批准号:
10555926 - 财政年份:2022
- 资助金额:
$ 11.32万 - 项目类别:
Regulation of nuclear calcium and ROS by Angiotensin II in heart cells. Régulation du calcium et ROS nucléaires par l'angiotensine II dans les cellules cardiaques.
血管紧张素 II 对心脏细胞中核钙和 ROS 的调节。
- 批准号:
RGPIN-2016-04414 - 财政年份:2021
- 资助金额:
$ 11.32万 - 项目类别:
Discovery Grants Program - Individual
Targeting cancer-associated fibroblasts and tumour hypoxia with angiotensin II receptor blockers
使用血管紧张素 II 受体阻滞剂靶向癌症相关成纤维细胞和肿瘤缺氧
- 批准号:
445961 - 财政年份:2021
- 资助金额:
$ 11.32万 - 项目类别:
Operating Grants
Intratubular Angiotensin II and AT1a Receptors in The Proximal Tubules: Roles in Hypertension and Kidney Injury
近曲小管中的管内血管紧张素 II 和 AT1a 受体:在高血压和肾损伤中的作用
- 批准号:
10164776 - 财政年份:2020
- 资助金额:
$ 11.32万 - 项目类别:
Novel Roles of Mitochondrial Angiotensin II in The Proximal Tubule of The Kidney
线粒体血管紧张素 II 在肾近端小管中的新作用
- 批准号:
10251271 - 财政年份:2020
- 资助金额:
$ 11.32万 - 项目类别:
Protection and organ injury by angiotensin II treatment for septic shock
血管紧张素II治疗感染性休克的保护作用和器官损伤
- 批准号:
20K09284 - 财政年份:2020
- 资助金额:
$ 11.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




